Edmonton, Alberta, Canada/January 5, 2023 – Pacylex, today announced that CEO Michael Weickert will present an update on clinical progress of PCLX-001 and Series B plans for Pacylex Pharmaceuticals at Biotech Showcase™ 2023.
Date: Tuesday, January 10, 2023
Time: 10:45am PT
Track: Franciscan A
"We are delighted to be presenting again at Biotech Showcase, which has always been an important venue to start our New Year. This year is more important than ever as we have made great progress in patients and are raising capital for two efficacy studies in blood cancers that could prove pivotal." said Michael Weickert, CEO of Pacylex.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that Pacylex will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
PCLX-001 is a N-myristoyl-transferase (NMT) inhibitor being developed as a once-a-day pill for leukemia and lymphoma. PCLX-001 selectively and potently inhibits both NMT1 and NMT2 and has been shown to regress lymphoma and leukemia tumors and inhibit the growth of lung and breast cancer tumors in animal models. In leukemia and lymphoma, the levels of NMT2 are correlated with survival, suggesting an important biological role in these cancers. A Phase 1 Trial of PCLX-001 in patients with relapsed/refractory B-cell Non-Hodgkin’s Lymphoma and advanced solid malignancies is currently in progress, and a second Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML) is planned to start Q2 2023. The FDA has granted PCLX-001 Orphan Drug Designation and Fast Track Designation for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
Pacylex is a clinical-stage pharmaceutical company headquartered in Edmonton, Alberta, Canada, developing a first-in-class, once daily oral cancer therapy with a novel targeted mechanism of action, PCLX-001. PCLX-001 is the lead drug in a new class of N-myristoyl-transferase (NMT) inhibitors, enabling Pacylex to exploit myristoylation as a new clinical target for cancer treatment. Pacylex is conducting a Phase 1 dose escalation study in Canada in patients with non-Hodgkin lymphoma and solid tumors. Pacylex received support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation. A second Phase 1 dose escalation study in patients with acute myeloid leukemia (AML) being supported by the US Department of Defense is planned to start Q2 2023.
About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
Contact: Michael J. Weickert